News
FDA presses on compounded GLP-1s with tirzepatide recall and Houston warning letter
A nationwide recall of compounded tirzepatide and a warning letter to a Houston compounder arrive as FDA says retatrutide cannot legally be compounded.
By the RetaRadar editors · Published November 3, 2026
The Food and Drug Administration is pressing on compounded and unapproved GLP-1 drugs on several fronts. In recent weeks, a compounder’s nationwide recall of tirzepatide injections drew national coverage. A warning letter to a Houston compounding pharmacy was also reported. And FDA’s updated consumer page states plainly that retatrutide cannot be compounded under federal law.
The actions differ in scope, but together they show where the agency is focusing: sterile manufacturing quality, compounded copies of approved drugs, and investigational ingredients sold outside any approved channel.
What FDA says about retatrutide
FDA’s page on unapproved GLP-1 drugs used for weight loss, marked current as of October 1, 2026, says retatrutide and cagrilintide “cannot be used in compounding under federal law.” The agency notes that neither is an ingredient in any FDA-approved drug. Neither has been found safe and effective for any condition.
FDA says it has warned three kinds of companies about retatrutide. The first is telehealth companies marketing it, some directly to consumers. The second is ingredient distributors selling it to compounders. The third is outsourcing facilities repackaging it.
The agency has also warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labeled “for research purposes” or “not for human consumption.” FDA says these products were sold to consumers for human use, and it urges people not to buy them.
Retatrutide remains an investigational drug. Its late-stage trial results have drawn wide attention, but FDA has not approved it for any use. Our retatrutide guide covers its mechanism, trials and regulatory status.
A nationwide recall and a warning letter
The Boston Globe reported on October 21 that Apothecary Pharma LLC voluntarily recalled compounded tirzepatide injections on September 24. The company cited possible contaminants, including microbes. The recall covers 22 lots. Brand-name Mounjaro and Zepbound are not affected.
According to the Globe, FDA classified the recall on October 8 as carrying a “remote” chance of serious health effects. The paper also reported that FDA had warned the company in March that investigators “noted serious deficiencies” in its sterility practices.
Separately, the MedShadow Foundation reported on October 29 that FDA sent a warning letter dated September 18, 2026 to Empower Clinic Services LLC, doing business as Empower Pharmacy. Empower is a 503A compounding pharmacy in Houston. The letter followed an FDA inspection that ran from November 3 to November 14, 2025.
As summarized by MedShadow, FDA found that Empower’s tirzepatide/niacinamide and semaglutide/cyanocobalamin products were essentially copies of approved drugs rather than preparations made for individual patients. FDA also found that sterile products had been prepared, packed or held under insanitary conditions. RetaRadar relied on MedShadow’s summary for these details and did not review the full letter text.
Why compounded GLP-1s have persisted
The Globe notes that the GLP-1 shortage ended in 2025. After that, compounded production of copies was supposed to stop. Lower prices have kept demand for alternatives going.
The paper cites a JAMA Health Forum study finding that many compounders kept making GLP-1 products after the shortage by adding other ingredients. The Empower products described in the warning letter pair tirzepatide or semaglutide with an added vitamin compound. The Globe also cites a July Gallup report finding that about 1 in 5 GLP-1 users now take such alternatives.
FDA’s page puts some numbers on the safety picture. As of May 31, 2026, the agency had received 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. FDA says these figures are probably undercounts, because ordinary state-licensed pharmacies are not required to report adverse events to the agency.
FDA is also working upstream. It has set up a “green list” import alert, numbered 66-80, meant to keep GLP-1 ingredients with possible quality problems out of the US supply chain.
What this means for patients
Zepbound, Mounjaro, Wegovy and Ozempic are FDA-approved. FDA recommends using compounded drugs only when a patient’s needs cannot be met by an FDA-approved drug. It also advises filling prescriptions at a state-licensed pharmacy, and its BeSafeRx program helps consumers identify legitimate online pharmacies.
Anyone considering a GLP-1 medicine should talk with a licensed clinician about whether an approved drug fits their situation. Products marketed as “research use only” are a named FDA enforcement target and are not a substitute for prescribed medicine.
For background on how FDA warnings apply to counterfeit and compounded products, see our explainer on fake and compounded GLP-1 drugs. Readers weighing approved options can also review our overview of Zepbound vs Wegovy cost and insurance coverage.
Sources
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration, October 1, 2026)
- Compounded GLP-1 drugs recalled amid rising concerns over unapproved weight-loss alternatives (The Boston Globe, October 21, 2026)
- FDA Recalls and Warnings, Empower Pharmacy warning letter summary (MedShadow Foundation, October 29, 2026)